| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $11.4M | -20.5% | -25.3% |
| SG&A Expense | $6.0M | -39.7% | +25.6% |
| Operating Income | -$17.4M | +28.3% | +13.3% |
| Net Income | -$16.2M | +29.0% | +14.5% |
| EPS (Basic) | -$0.16 | +27.3% | +40.7% |
| EPS (Diluted) | -$0.16 | +27.3% | +40.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $11.2M | -5.9% | -23.0% |
| Short-term Investments | $109.0M | -9.9% | +50.8% |
| Current Assets | $122.0M | -9.7% | +37.5% |
| Total Assets | $125.5M | -9.5% | +32.4% |
| Current Liabilities | $7.7M | -19.2% | -26.8% |
| Total Liabilities | $8.6M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$51.5M | — | — |
| Investing Cash Flow | -$33.4M | — | — |
| Financing Cash Flow | $2.0M | — | — |
| -29.1% |
| Stockholders' Equity | $116.8M | -8.7% | +41.5% |